Board of Directors
Board of Directors
Arie Belldegrun, M.D.
Dr. Belldegrun is the Chairman of UroGen Pharma. He has built a distinguished career as a visionary surgeon, scientist, and life sciences entrepreneur.
Dr. Belldegrun founded Kite Pharma, a biopharmaceutical company engaged in the development of innovative cancer immunotherapies, where he served as Chairman, President, and Chief Executive Officer until the acquisition of Kite by Gilead Sciences in October 2017.
Dr. Belldegrun has had a distinguished tenure in the life sciences, having been closely involved with the founding and advancement of several successful biopharmaceutical companies, including Cougar Biotechnology and Agensys. Abiraterone, developed by Cougar, is a mainstay of therapy for patients with metastatic prostate cancer.
Dr. Belldegrun most recently co-founded Allogene Therapeutics, a clinical stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (CAR T) therapies for cancer. He serves as Executive Chairman of Allogene; Chairman of Two River Group and Kronos Bio; Co-Founder and Senior Managing Director of Vida Ventures, a life science venture group; and co-Chairman of Breakthrough Properties, a life science real estate development company.
Dr. Belldegrun is a Professor of Urology, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. He is currently a member of the Parker Institute for Cancer Immunotherapy Strategic Advisory Group.
Prior to joining UCLA, Dr. Belldegrun served as a research fellow in surgical oncology and immunotherapy under Dr. Steven A. Rosenberg at the National Cancer Institute/NIH. He completed his doctor of medicine at the Hebrew University Hadassah Medical School in Jerusalem, his post-graduate studies in immunology at the Weizmann Institute of Science, and his residency in urologic surgery at Harvard Medical School. He has authored several books in oncology and more than 500 scientific and medical papers related to urological cancers, immunotherapy, gene therapy, and cancer vaccines. He is certified by the American Board of Urology and is a fellow of the American Association of Genitourinary Surgeons.
President and Chief Executive Officer
Ms. Barrett is a highly regarded industry leader with extensive experience leading business organizations and Fortune 500 pharmaceutical companies.
Prior to UroGen, Ms. Barrett was CEO of Novartis Oncology and a member of the Novartis Executive Committee.
She previously served as Global President of Oncology at Pfizer Inc., where she held numerous leadership positions, including President of Global Innovative Pharma for Europe, President of the Specialty Care Business Unit for North America, and President of United States Oncology.
Prior to Pfizer, Ms. Barrett held positions at Cephalon Inc., where she was Vice President and General Manager of the Oncology Business Unit, and at Johnson & Johnson. She started her career at Kraft Foods Group Inc.
Ms. Barrett holds a master of business administration from Saint Joseph’s University and a bachelor of science from the University of Louisiana.
Ms. Butitta is a seasoned financial and operational executive with more than 25 years of leadership experience in both the biotechnology and high-technology industries. She has served as a director for UroGen since November 2017.
Most recently, Ms. Butitta served as Chief Operating Officer of Kite Pharma, where she played an instrumental role in the acquisition of Kite Pharma by Gilead Sciences for approximately $11.9 billion in cash. She also served as Kite Pharma’s Executive Vice President and Chief Financial Officer from 2014 to 2016. During her tenure at Kite, Ms. Butitta was responsible for securing more than $1 billion in equity financing and oversaw the rapid growth of the organization.
Prior to joining Kite, Ms. Butitta served as Senior Vice President and Chief Financial Officer of NextWave Pharmaceuticals, Inc., which was acquired in 2012 by Pfizer, Inc. for $700 million.
Previously, Ms. Butitta held positions as Chief Operating Officer and Chief Financial Officer of Telik Inc., a public biotechnology company focused on the development of small molecule drugs for the treatment of cancer, prior to its acquisition by MabVax Therapeutics, Inc.
Ms. Butitta was also Vice President of Finance and Administration and Chief Financial Officer for Connetics, Inc., a public biotechnology company.
Ms. Butitta received a bachelor of science degree with honors in business and accounting from Edgewood College in Madison, WI, and a master of business administration in finance from the University of Wisconsin, Madison.
Fred E. Cohen, M.D.
Dr. Cohen is a former academic clinician with many years of experience advising pharmaceutical and life sciences companies. Dr. Cohen has served as a director for UroGen since May 2017.
Dr. Cohen is a Senior Advisor to TPG Capital, where he served for more than 15 years as a partner and founder of TPG Biotech, a life science-focused venture capital fund.
For more than two decades throughout his career, Dr. Cohen has been affiliated with the University of California, San Francisco, where he has held various clinical positions, including as a research scientist, an internist for hospitalized patients, a consulting endocrinologist, and the Chief of the Division of Endocrinology and Metabolism.
Dr. Cohen earned a doctor of philosophy in molecular biophysics on a Rhodes Scholarship from Oxford University, a doctor of medicine from Stanford University, and a bachelor of science in molecular biophysics and biochemistry from Yale University.
Dr. Cohen currently serves on the board of directors of several other biotechnology and pharmaceutical companies.
Ms. Falberg is a veteran business executive who has served as a board member for a number of highly successful companies. Ms. Falberg has served as a director for UroGen since April 2017.
Throughout her career, Ms. Falberg has held several CFO and Head of Strategy and Corporate Development roles in the technology and biotechnology industries, including for Applied Magnetics, Amgen, and, most recently, Jazz Pharmaceuticals.
Ms. Falberg currently sits on the board of directors of several pharmaceutical and technology companies: Aimmune Therapeutics, aTyr Pharma, Axovant Sciences, BioMarin Pharmaceutical, and The Trade Desk. She has also formerly served on multiple other boards, including Medivation and Halozyme Therapeutics.
Ms. Falberg holds a bachelor of arts and a master of business administration from UCLA and is a CPA (inactive) and a UCLA-certified director.
Stuart Holden, M.D.
Dr. Holden has a long and decorated career as a practicing urologist, research pioneer in prostate and urologic cancers, and an academic. He has served as a director for UroGen since December 2015.
Dr. Holden has been the Chairman of ProQuest Investments’ Scientific Advisory Board since its founding.
Since 2014, Dr. Holden has held a number of positions within the Department of Urology at the David Geffen School of Medicine at UCLA, including Health Sciences Clinical Professor of Urology, Spielberg Family Chair in Urologic Oncology, and Associate Director of the UCLA Institute of Urologic Oncology.
Dr. Holden has worked on the front lines of prostate cancer for more than 36 years and has pioneered new treatments for urologic cancers. Dr. Holden’s dedication to patient care resulted in him being named Medical Director of the Prostate Cancer Foundation, the world’s largest funding organization of prostate cancer research; he has held this position since the foundation’s inception in 1993.
Dr. Holden previously held a position as the director of the Louis Warschaw Prostate Cancer Center at Cedars-Sinai Medical Center, and was the first holder of the Warschaw, Robertson, Law Families Chair in Prostate Cancer.
Dr. Holden was also a founding partner of Tower Urology in Los Angeles.
Dr. Holden completed his medical degree and received his surgical training at Weill Cornell Medical College and the New York Hospital-Cornell University Medical College. He completed his urology residency at Emory University School of Medicine and fellowships in urology and developmental genetics at Memorial Sloan-Kettering Cancer Center. He was also awarded a clinical fellowship from the American Cancer Society and received a bachelor of arts degree from the University of Wisconsin-Madison.
Mr. Nussbaum is a successful entrepreneur and executive with deep expertise in the business of the pharmaceutical industry. His work revolves around constant and active involvement in companies, providing them with strategic and business development oversight.
Mr. Nussbaum is a managing partner and co-founder of Pontifax, a firm that runs 6 different funds and more than 75 portfolio companies around the globe. The group has established more than 19 startups since it was incorporated in 2005.
In the past, Mr. Nussbaum served on the board of directors for Kite Pharma (sold to Gilead) and cCEM Therapeutics (sold to Merck). He has also chaired Ocon Medical, and NasVax Therapeutics and was CEO at Spearhead Ltd. and Biomedix Ltd.
Currently Mr. Nussbaum sits on the board of many of Pontifax’s portfolio companies, including: Eloxx (ELOX), UroGen (URGN), ArQule (ARQL), Prevail (PRVL) and Lutris. He also serves as Keros Therapeutics’ chairman of the board.
Shawn C. Tomasello
Ms. Tomasello brings more than 30 years of experience in the life sciences industry to her role as a director of UroGen.
Most recently, Ms. Tomasello served as Chief Commercial Officer of Kite Pharma (subsequently Kite, a Gilead Company), where she led the commercialization of YescartaTM (axicabtagene ciloleucel), the first approved chimeric antigen receptor (CAR) T therapy for the treatment of adult patients with relapsed or refractory non-Hodgkin’s lymphoma.
Prior to joining Kite, Ms. Tomasello served as Chief Commercial Officer at Pharmacyclics, Inc., during which time the brand Imbruvica® (ibrutinib) was awarded the prestigious Prix Galien USA Award 2015 for Best Pharmaceutical Agent.
Previously, Ms. Tomasello held senior leadership positions at Celgene Corporation, including President of the Americas, Hematology and Oncology, in which she oversaw more than $4 billion in product revenues. During her tenure at Celgene, Ms. Tomasello was responsible for all aspects of commercial sales and marketing for five brands encompassing 11 indications. One of these brands, Revlimid® (lenalidomide), was awarded the Prix Galien USA 2008 Award for Special Therapeutic Development.
Prior to this, Ms. Tomasello was National Director of Hematology for Rituxan® (rituximab) at Genentech, representing the most significant portion of the company’s product revenue during her tenure.
Earlier in her career, Ms. Tomasello held positions at Pfizer Laboratories, Miles Pharmaceuticals, and Proctor & Gamble.
Ms. Tomasello currently serves on the boards of directors of Centrexion Therapeutics, Oxford BioTherapeutics, and Diplomat Specialty.
Ms. Tomasello holds a master of business administration from Murray State University and a bachelor of science degree in marketing from the University of Cincinnati.